

ARDEN CANCER CENTER TO BENEFIT FROM CLINICAL DECISION SUPPORT SYSTEMS FROM IMPAC MEDICAL SYSTEMS AND FIRST DATABANK EUROPE

PRESS RELEASE

Stockholm, Sweden, December 15, 2006

The Arden Cancer Centre, part of the University Hospitals Coventry and Warwickshire NHS Trust, is set to benefit from clinical decision support following the successful implementation of software from IMPAC Medical Systems, an Elekta Company, supported by First DataBank Europe's (FDBE) drug knowledge base.

The Trust has selected IMPAC to implement their oncology specific image-enabled electronic medical record system to improve overall workflow and practice management and to enhance care for cancer patients. The system includes FDBE's comprehensive decision support, which is designed to improve patient safety by helping clinicians reduce medication errors at the point of prescribing. The system also has the ability to audit clinicians' responses to warnings.

Dr Clive Irwin, Clinical Oncologist, University Hospitals Coventry and Warwickshire NHS Trust, comments: "Patients at the Arden Centre rely on clinicians for the best possible care. We have selected this system, designed specifically for the context we work in, to provide vital patient and drug data and clinical decision support necessary for us to select the best medicines and treatments for each individual to ensure patient safety."

Menna Kime, Product Marketing Specialist at IMPAC, adds: "As a specialist developer of oncology data management systems across the spectrum of cancer care, we are proud to have been selected to provide a solution for the new Oncology Unit at the Arden Cancer Centre. We have partnered with FDBE as it has unrivalled expertise and knowledge in clinical decision support. This system has been devised with cancer patients in mind to support prescribing and dispensing for oncology clinicians."

Keith Kirtland, Sales and Marketing Director at FDBE says "We are thrilled to be part of this successful implementation that will see our products providing real value to clinicians and helping to improve care in this vital field."

For further information, please contact:

For further information, please contact:

<u>Product inquiries:</u> Nicky Wilson

European Product Marketing Manager, IMPAC

Tel: +44 (0) 1293 654508 Email: nicky.wilson@elekta.com

Investor inquiries:

Peter Ejemyr

Group VP Corporate Communications, Elekta AB

Tel: +46 733 611 000

Email: peter.ejemyr@elekta.com



About First DataBank Europe

First DataBank Europe (FDBE) enables safer prescribing and dispensing and improved patient care through effective clinical decision support. Through its partnerships with healthcare system providers, FDBE's decision support is in daily use by thousands of healthcare professionals in the UK. NHS Connecting for Health has chosen First DataBank Europe to provide drug related clinical decision support for the National Program for IT.

FDBE supplies data and software to an impressive portfolio of system suppliers serving clinicians in hospitals, community pharmacies, GP practices and other healthcare environments. Its Multilex Drug Data File - the UK's most widely used drug knowledge base - is integrated into clinical systems across the whole healthcare community to support safer prescribing and dispensing and improve patient care.

For further information visit www.firstdatabank.co.uk

About IMPAC

IMPAC Medical Systems, an Elekta company, was founded in 1990 to develop an integrated clinical and administrative information management system tailored specifically for cancer care; today IMPAC has more than 3000 installations spanning 56 countries worldwide – including more than half of the top 50 U.S. cancer centers. Specializing in the development of practice management, electronic patient record, image management, and statistical reporting software, IMPAC offers practical solutions that help healthcare providers more efficiently manage the process of delivering cancer care.

For further information visit www.impac.com

About Elekta

Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective.

Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software.

Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders.

With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.